Results
REMISSION
Both sensitivity and negative predictive value (NPV) were higher for the remission outcome than for the response outcome. The interpretation of sensitivity and NPV in the lurasidone group when remission is an outcome is as follows. It means (1) that, from all remitters at Week 6, 80.6% was identified as such at Week 2 on the basis of their early improvement and (2) that a patient showing non‐improvement at 2 weeks had 93.5% probability of being a non‐remitters at Week 6. However, the values of specificity for both response and remission in the lurasidone group were not high.